Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2016, Article ID 1423131, 6 pages
http://dx.doi.org/10.1155/2016/1423131
Case Report

Adalimumab Induced or Provoked MS in Patient with Autoimmune Uveitis: A Case Report and Review of the Literature

1Division of Neurology, Department of Internal Medicine, Aleppo University Hospital, Aleppo, Syria
2Division of Rheumatology, Department of Internal Medicine, Aleppo University Hospital, Aleppo, Syria

Received 16 June 2016; Accepted 3 October 2016

Academic Editor: Malcolm E. Molyneux

Copyright © 2016 Rana Alnasser Alsukhni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Caminero, M. Comabella, and X. Montalban, “Tumor necrosis factor alpha (TNF-α), anti-TNF-α and demyelination revisited: an ongoing story,” Journal of Neuroimmunology, vol. 234, no. 1-2, pp. 1–6, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. M. F. Doran, C. S. Crowson, G. R. Pond, W. M. O'Fallon, and S. E. Gabriel, “Frequency of infection in patients with rheumatoid arthritis compared with controls: A Population-Based Study,” Arthritis and Rheumatism, vol. 46, no. 9, pp. 2287–2293, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Haraoui and E. Keystone, “Musculoskeletal manifestations and autoimmune diseases related to new biologic agents,” Current Opinion in Rheumatology, vol. 18, no. 1, pp. 96–100, 2006. View at Google Scholar · View at Scopus
  4. M. Ramos-Casals, P. Brito-Zerón, S. Muñoz et al., “Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases,” Medicine, vol. 86, no. 4, pp. 242–251, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Marchesoni, M. Arreghini, B. Panni, N. Battafarano, and L. Uziel, “Life-threatening reversible bone marrow toxicity in a rheumatoid arthritis patient switched from leflunomide to infliximab,” Rheumatology, vol. 42, no. 1, pp. 193–194, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Rajakulendran, K. Gadsby, D. Allen, S. O'Reilly, and C. Deighton, “Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 65, no. 12, pp. 1678–1679, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Schoe, N. E. Van Der Laan-Baalbergen, T. W. J. Huizinga, F. C. Breedveld, and J. M. Van Laar, “Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab,” Arthritis Care and Research, vol. 55, no. 1, pp. 157–159, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. E. S. Chung, M. Packer, K. H. Lo, A. A. Fasanmade, and J. T. Willerson, “Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial,” Circulation, vol. 107, no. 25, pp. 3133–3140, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Askling, C. M. Fored, E. Baecklund et al., “Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists,” Annals of the Rheumatic Diseases, vol. 64, no. 10, pp. 1414–1420, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Baker, D. Butler, B. J. Scallon, J. K. O'Neill, J. L. Turk, and M. Feldmann, “Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins,” European Journal of Immunology, vol. 24, no. 9, pp. 2040–2048, 1994. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Selmaj, W. Papierz, A. Glabinski, and T. Kohno, “Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I,” Journal of Neuroimmunology, vol. 56, no. 2, pp. 135–141, 1995. View at Publisher · View at Google Scholar · View at Scopus
  12. B. W. Van Oosten, F. Barkhof, L. Truyen et al., “Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2,” Neurology, vol. 47, no. 6, pp. 1531–1534, 1996. View at Publisher · View at Google Scholar · View at Scopus
  13. N. Mohan, E. T. Edwards, T. R. Cupps et al., “Demyelination occurring during anti-tumor necrosis factor α therapy for inflammatory arthritides,” Arthritis and Rheumatism, vol. 44, no. 12, pp. 2862–2869, 2001. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Andreadou, E. Kemanetzoglou, Ch. Brokalaki et al., “Demyelinating disease following anti-TNFa treatment: a causal or coincidental association? Report of four cases and review of the literature,” Case Reports in Neurological Medicine, vol. 2013, Article ID 671935, 9 pages, 2013. View at Publisher · View at Google Scholar
  15. R. Seror, C. Richez, C. Sordet et al., “Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey,” Rheumatology, vol. 52, no. 5, pp. 868–874, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. E. Kaltsonoudis, A. K. Zikou, P. V. Voulgari, S. Konitsiotis, M. I. Argyropoulou, and A. A. Drosos, “Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study,” Arthritis Research and Therapy, vol. 16, no. 3, article R125, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. S. M. Malinowski, J. S. Pulido, N. E. Goeken, C. K. Brown, and J. C. Folk, “The association of HLA-B8, B51, DR2, and multiple sclerosis in pars planitis,” Ophthalmology, vol. 100, no. 8, pp. 1199–1205, 1993. View at Publisher · View at Google Scholar · View at Scopus
  18. É. Toussirot, É. Pertuiset, A. Martin et al., “Association of rheumatoid arthritis with multiple sclerosis: report of 14 cases and discussion of its significance,” Journal of Rheumatology, vol. 33, no. 5, pp. 1027–1029, 2006. View at Google Scholar · View at Scopus
  19. A. Calin, “Is there an association between ankylosing spondylitis and multiple sclerosis?” Annals of the Rheumatic Diseases, vol. 48, no. 12, pp. 971–972, 1989. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Ruiz-Jimeno, A. Carvajal, C. Mata, and E. Aurrecoechea, “Demyelinating disease in a patient with psoriatic arthritis and family history of multiple sclerosis treated with infliximab,” Journal of Rheumatology, vol. 33, no. 7, pp. 1457–1458, 2006. View at Google Scholar · View at Scopus
  21. N. L. Sicotte and R. R. Voskuhl, “Onset of multiple sclerosis associated with anti-TNF therapy,” Neurology, vol. 57, no. 10, pp. 1885–1888, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Winkelmann, R. Patejdl, S. Wagner, R. Benecke, and U. K. Zettl, “Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapy,” Journal of Neurology, vol. 255, no. 6, supplement 6, pp. 109–114, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. W. H. Robinson, M. C. Genovese, and L. W. Moreland, “Demyelinating and neurologic events reported in association with tumor necrosis factor α antagonism: by what mechanisms could tumor necrosis factor α antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?” Arthritis and Rheumatism, vol. 44, no. 9, pp. 1977–1983, 2001. View at Google Scholar · View at Scopus
  24. G. Kassiotis and G. Kollias, “Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination,” Journal of Experimental Medicine, vol. 193, no. 4, pp. 427–434, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. “Multiple sclerosis and other demylination diseases of the central nervous system,” in Bradley's Neurology in Clinical Practice, chapter 380, p. 1318, 6th edition, 2012.
  26. I. Casetta, G. Iuliano, and G. Filippini, “Azathioprine for multiple sclerosis,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD003982, 2007. View at Google Scholar · View at Scopus
  27. N. De Stefano, E. Cocco, M. Lai et al., “Imaging brain damage in first-degree relatives of sporadic and familial multiple sclerosis,” Annals of Neurology, vol. 59, no. 4, pp. 634–639, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Gabelic, D. P. Ramasamy, B. Weinstock-Guttman et al., “Prevalence of radiologically isolated syndrome and white matter signal abnormalities in healthy relatives of patients with multiple sclerosis,” American Journal of Neuroradiology, vol. 35, no. 1, pp. 106–112, 2014. View at Publisher · View at Google Scholar · View at Scopus